Health

vaccinated. Serial antibody testing is costly and a bit difficult, but it is pretty likely that antivirals are suppressing the natural antibody response (and likely the T-cells similarly)--which is likely insufficient to begin with for many receiving these meds. That the researchers pulled these patients from a parent study (Positives) for which prior vaccine status was apparently known but did not address this nor explain how exclusion criteria might have addressed it is curious.

Still, many who did receive it here are at such high risk from natural infection, the risk: benefit likely favors Paxlovid. But for that study to not even address the issue (not to mention it was not a randomized controlled study, but merely observational), leaves more questions than answers.